Leaked news from the future.
Tap to receive
A Biologics License Application for intismeran autogene will be submitted to the FDA by June 30, 2027. The filing will follow the August 19, 2026 topline INTerpath-001 readout that met recurrence-free survival and distant metastasis-free survival, and will come after Moderna and Merck said they wou…